EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

MethMarkerDB 2.0: an expanded and functionally annotated database for cancer DNA methylation biomarkers

Yuanhui Sun iD, Zongyang Peng, Linyun Zhong, Zihe Li, Yunzhao Hao, Qiangwei Zhou iD, Guoliang Li iD

Nucleic Acids Research · 11.11.2026

DOI: 10.1093/nar/gkag1109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 11.11.2026. Verfasst von Yuanhui Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Crop Genetic Improvement, Wuhan 430070, China. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hubei Province, Central Universities.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer-associated differentially methylated regions (DMRs) are promising biomarkers for cancer diagnosis, prognosis, and therapeutic response, but their biological significance and potential applications remain to be systematically explored across datasets. To support this, we released MethMarkerDB 2.0 (https://methmarkerdb.hzau.edu.cn/v2), which provides several improvements over the previous version: (i) Expands the data resource from 13 to 21 cancer types and from 658 to 1236 whole-genome methylome samples, comprising ∼5.6 million candidate DMRs and 6411 literature-curated biomarker records.(ii) Integrates 450K DNA methylation data from The Cancer Genome Atlas and Epigenome-Wide Association Study Atlas and transcript annotations into the “MethMarker Gene Search” module. These data provide complementary evidence from independent datasets and platforms and allow users to examine CpG-level information for individual DMRs. Additionally, cell-type-resolved reference methylation data allow users to check cellular-background methylation. (iii) Introduces four analysis modules to characterize DMR methylation patterns across age groups and spatial ecotypes, and connect DMRs with transcription factor binding evidence and cancer cell-line drug responses. Moreover, the “Methylation-Cas Designer” supports guide RNA design for methylation-sensitive restriction enzyme–Cas assays and targeted epigenome editing. In summary, MethMarkerDB 2.0 provides expanded resources, diverse functional analyses, and experimental design tools, facilitating the interpretation and application of cancer-associated DMRs.

Autor:innen und Institutionen

  • National Key Laboratory of Crop Genetic Improvement, Wuhan 430070, China.
  • Hubei Hongshan Laboratory, Huazhong Agricultural University, Wuhan 430070, China.
  • Agricultural Bioinformatics Key Laboratory of Hubei Province, Hubei Engineering Technology Research Center of Agricultural Big Data, 3D Genomics Research Center, College of Informatics, Huazhong Agricultural University,…

ORCID-Profile: Yuanhui Sun, Qiangwei Zhou, Guoliang Li

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Hubei Province
  • Central Universities

Zitieren

APA

Sun, Y., Peng, Z., Zhong, L., Li, Z., Hao, Y., Zhou, Q., & Li, G. (2026). MethMarkerDB 2.0: an expanded and functionally annotated database for cancer DNA methylation biomarkers. Nucleic Acids Research. https://doi.org/10.1093/nar/gkag1109

Vancouver

Sun Y, Peng Z, Zhong L, Li Z, Hao Y, Zhou Q, et al. MethMarkerDB 2.0: an expanded and functionally annotated database for cancer DNA methylation biomarkers. Nucleic Acids Research. 2026. doi:10.1093/nar/gkag1109

BibTeX
@article{Sun2026,
  author = {Sun, Yuanhui and Peng, Zongyang and Zhong, Linyun and Li, Zihe and Hao, Yunzhao and Zhou, Qiangwei and Li, Guoliang},
  title = {MethMarkerDB 2.0: an expanded and functionally annotated database for cancer DNA methylation biomarkers},
  journal = {Nucleic Acids Research},
  year = {2026},
  doi = {10.1093/nar/gkag1109}
}
Kostenlos starten →